Damora Therapeutics, Inc. Ordinary Shares
DMRA
25 hedge funds and large institutions have $21M invested in Damora Therapeutics, Inc. Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.08% less ownership
Funds ownership: 1.59% → 1.51% (-0.08%)
31% less capital invested
Capital invested by funds: $30.5M → $21M (-$9.43M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$20.8K |
| 2 |
JP Morgan Chase
New York
|
+$3.99K |
| 3 |
Millennium Management
New York
|
+$2.53K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.36K |
| 5 |
Morgan Stanley
New York
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$556K |
| 2 |
Two Sigma Advisers
New York
|
-$315K |
| 3 |
Two Sigma Investments
New York
|
-$254K |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$79.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
DMRA Hedge Fund Activity: Q1 2022 in Review
25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2022, worth a combined $21M — down 31% from $30.5M a quarter earlier.
Fund positioning in DMRA was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 8 trimmed.
The largest buyer was Marquette Asset Management, adding an estimated $20.8K. The largest seller was Anson Funds Management, exiting entirely with an estimated $556K sold.
- 25 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $21M of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2022, down 31% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2022 and 3 closed out, a net change of 0 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2022 was Marquette Asset Management, an estimated $20.8K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2022 was Anson Funds Management, an estimated $556K sold.
Based on aggregated 13F filings for Q1 2022.